Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4582 Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4480 Efficacy of regional and systemic therapies for refractory hypoglycaemia in malignant insulinoma

Introduction: Insulinoma is a rare neuroendocrine tumour characterised by inappropriate autonomous insulin secretion.

Conference:

Presenting Author: Koch R

Authors: Koch R, McGarrah P, Eiring R, Hobday T, Halfdanarson T,

Keywords: Insulinoma, radioligand therapy,

#4465 RET Lys666Asn has low MEN2-related tumours penetrance but may be associated with pheochromocytoma

Introduction: Multiple Endocrine Neoplasia type 2 (MEN2) is caused by germline pathogenic variants (PVs) in the RET proto-oncogene, leading to medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism (PHPT). RET c.1998G>C, p.Lys666Asn is a rare PV, with 33 cases described thus far, and is associated with low penetrance of MEN2-related tumours, but its clinical significance remains incompletely understood.

Conference:

Presenting Author: Halperin R

Authors: Halperin R, Peshes-Yaloz N, Tirosh A, Twito O,

Keywords: MEN2, pheochromocytoma, hyperparathyroidism, medullary thyroid carcinoma,